Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On June21, 2018, William Welch, the Chief Executive Officer of Trovagene,Inc. (the “Company”), notified the Board of Directors of his resignation as Chief Executive Officer and a director of the Company for personal reasons. On June22, 2018, the Board appointed Dr.Thomas Adams, the Company’s Chairman, to serve as interim Chief Executive Officer, effective immediately. The Company has a succession planning process in place and has begun a search for a permanent Chief Executive Officer.
Dr.Adams has been the Company’s Chairman of the Board since April2009.From June2005 through 2011, Dr.Adams served as a director of IRIS International,Inc., a diagnostics company, and served as Chief Technology Officer of IRIS since April2006.Dr.Adams was the Head of Iris Molecular Diagnostics from 2006 untilNovember 2012and served as the President of Iris Personalized Medicine.In November2012, IRIS was acquired by Danaher Corporation. Dr.Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April2006, whenLeucadiawas acquired by IRIS.Dr.Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997.Dr.Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989.Dr.Adams holds a Ph.D. in Biochemistry from theUniversity of California, at Riverside.
The Company announced Mr.Welch’s resignation and the appointment of Dr.Adams as interim CEO in a press release dated June22, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
| Item 5.02. | Financial Statements and Exhibits |
(d) Exhibits.
| 99.1 | Press Release of Trovagene, Inc. dated June22, 2018 |
-2-
Trovagene, Inc. ExhibitEX-99.1 2 d830280dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Trovagene Announces Leadership Change William Welch has resigned as CEO and Director Dr. Thomas Adams,…To view the full exhibit click here
About Trovagene,Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
